Jump to content

BioMérieux

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 199.48.76.58 (talk) at 01:50, 19 February 2020 (→History). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

bioMérieux
Company typeSociété Anonyme
Euronext: BIM
IndustryBiotechnology
Founded1963; 61 years ago (1963)
FounderDr Alain Mérieux
HeadquartersMarcy-l'Étoile, France
Area served
Worldwide
Key people
Alexandre Mérieux
(CEO) Dr Marcel Mérieux, Dr Charles Mérieux
Productsin vitro diagnostics
Revenue€2.4 billion (2018)
587,000,000 Euro (2022) Edit this on Wikidata
452,000,000 Euro (2022) Edit this on Wikidata
Number of employees
11 200 (2018)
Websitewww.biomerieux.com

bioMérieux (Euronext: BIM) is a multinational biotechnology company founded and headquartered in France. bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors.[1]

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.[2] bioMérieux is listed on the NYSE Euronext Paris stock exchange (BIM – ISIN: FR0010096479).[3]

Revenue

bioMérieux had revenues of €2.103 billion as of 2016 with 90% of sales occurring outside France.[4] In year 2017, the company increased its annual revenue to €2.288 billion.[5] 2017 Annual Report

History

In 1897, Marcel Mérieux, former assistant to Louis Pasteur, founded the Mérieux Biological Institute, which later became Institut Mérieux. In 1963 Alain Mérieux founded BD Mérieux, of which he assumed total control in 1973. BD Mérieux would later become bioMérieux. The company expanded its services and offerings through product development, acquisitions and partnerships:

  • Api Systems, acquired in 1986[6]
  • Vitek Systems, acquired in 1988[7]
  • Organon Teknika, acquired in 2001 from Akzo Nobel[8]
  • Bacterial Barcodes, acquired in 2006[9]
  • Biomedics (Spain) and BTF (Australia), acquired in 2007[10]
  • AB Biodisk (Sweden), AviaraDx (bioTheragnostics today) (USA) and PML Microbiologicals (USA), acquired in 2008[11]
  • Meikang Biotech and of Shanghai Zenka Biotechnology, acquired in 2010[12]
  • AES Laboratoire and Argene (France), acquired in 2011[13]
  • RAS (India), a specialist in molecular biology, acquired in 2012
  • Partnership with Quanterix in 2012 for the development of a new generation of ultrasensitive, multiplex immunoassays.[14]
  • BioFire Diagnostics Inc., a privately held US-based company specialized in molecular biology,[15][16] acquired in 2014
  • BioMerieux molecular biology affiliate BioFire, LLC. opened the Alain Mérieux Center for Molecular Diagnostics in Salt Lake City, Utah[17] in 2017
  • Invisible Sentinel, A Philadelphia life sciences company that develops novel technology to quickly detect pathogens in food and beverages including wine and beer. [18]

Institut Mérieux, which belongs to the Mérieux family, is the main shareholder of bioMérieux. Jean-Luc Belingard is President, and Alexandre Mérieux is General Director.[19] *bioMérieux is listed on the stock exchange in 2004.[20]

References

  1. ^ https://www.euronext.com/en/products/equities/FR0010096479-XPAR/company-information
  2. ^ https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=23790762
  3. ^ https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=23790762
  4. ^ http://www.biomerieux.com/en/biomerieux-2016-financial-results
  5. ^ http://www.biomerieux-finance.com/sites/investord7/files/ddr_2017_gb_vdef.pdf
  6. ^ http://www.referenceforbusiness.com/history2/13/bioM-rieux-S-A.html
  7. ^ http://www.referenceforbusiness.com/history2/13/bioM-rieux-S-A.html
  8. ^ https://www.akzonobel.com/for-media/media-releases-and-features/akzo-nobel-transfers-organon-teknikas-diagnostics-business
  9. ^ https://scrip.pharmaintelligence.informa.com/deals/200610151
  10. ^ https://mergr.com/biomerieux-s.a.-acquires-btf-pty.
  11. ^ https://www.reuters.com/article/biomerieux/biomerieux-buys-u-s-microbiology-firm-idINL863440920081208
  12. ^ http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=272481
  13. ^ http://www.qualityassurancemag.com/article/qa-052011-biomerieux-acquires-aes-laboratoire/
  14. ^ http://www.quanterix.com/resources/press-releases/biomerieux-and-quanterix-sign-strategic-partnership-ultrasensitive-and
  15. ^ https://www.genomeweb.com/pcrsample-prep/biomerieux-finalizes-biofire-diagnostics-acquisition
  16. ^ https://www.reuters.com/article/biomerieux-biofire/biomerieux-buys-diagnostics-rival-biofire-for-450-mln-idUSL6N0H014H20130904
  17. ^ http://www.clpmag.com/2017/06/biofire-opens-center-molecular-diagnostics/
  18. ^ https://www.bizjournals.com/philadelphia/news/2019/02/07/75-million-deal-invisible-sentinel-sold-to-french.html
  19. ^ https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=23790762
  20. ^ https://invivo.pharmaintelligence.informa.com/IV002374/bioMerieux-a-FamilyOwned-French-Firm-Finally-Goes-Public
Retrieved from "https://en.wikipedia.org/w/index.php?title=BioMérieux&oldid=941517800"